Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Liabilities and Shareholders Equity (2023 - 2025)

Historic Liabilities and Shareholders Equity for CG Oncology (CGON) over the last 3 years, with Q3 2025 value amounting to $729.9 million.

  • CG Oncology's Liabilities and Shareholders Equity rose 3211.79% to $729.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 billion, marking a year-over-year increase of 5377.38%. This contributed to the annual value of $754.8 million for FY2024, which is 27872.21% up from last year.
  • As of Q3 2025, CG Oncology's Liabilities and Shareholders Equity stood at $729.9 million, which was up 3211.79% from $701.4 million recorded in Q2 2025.
  • In the past 5 years, CG Oncology's Liabilities and Shareholders Equity ranged from a high of $754.8 million in Q4 2024 and a low of $199.3 million during Q4 2023
  • Over the past 3 years, CG Oncology's median Liabilities and Shareholders Equity value was $640.3 million (recorded in 2024), while the average stood at $601.2 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first skyrocketed by 27872.21% in 2024, then skyrocketed by 2429.7% in 2025.
  • CG Oncology's Liabilities and Shareholders Equity (Quarter) stood at $199.3 million in 2023, then skyrocketed by 278.72% to $754.8 million in 2024, then decreased by 3.3% to $729.9 million in 2025.
  • Its last three reported values are $729.9 million in Q3 2025, $701.4 million for Q2 2025, and $728.2 million during Q1 2025.